Screening for JAK2 V617F point mutation in patients with hypereosinophilic syndrome-in response to 'Hypereosinophilic syndrome: another face of janus?' by Dahabreh et al. published in Leukemia Research, in press

Hypereosinophilic syndrome: another face of janus?. Leukemia Research 32(9): 1483-1485, 2008

Peripheral blood myeloid progenitor cell cultures in patients with hypereosinophilic syndrome (CFU-eos in hypereosinophilic syndrome). Blood 60(3): 721-726, 1982

Hypereosinophilic syndrome and eosinophilic leukemia: a comparison of 22 hypereosinophilic cats. Journal of the American Animal Hospital Association 30(6): 591-599, 1994

Hypereosinophilic dermatitis. A distinct manifestation of the hypereosinophilic syndrome with response to dapsone. Dermatologica 162(6): 444-450, 1981

Essential thrombocythemia with JAK2 V617F mutation transformed into acute myeloid leukemia without JAK2 V617F mutation:case report and literature review. Zhonghua Xue Ye Xue Za Zhi 35(12): 1122-1123, 2015

JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia. Korean Journal of Hematology 45(1): 46-50, 2010

Study of release of eosinophil cationic proteins in the hypereosinophilic syndrome and other hypereosinophilic conditions. Panminerva Medica 40(3): 186-190, Sept, 1998

Hypereosinophilic dermatosis: skin lesions as the only manifestation of the idiopathic hypereosinophilic syndrome?. British Journal of Dermatology 143(3): 675-677, 2000

Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation. Leukemia and Lymphoma 51(10): 1941-1943, 2011

JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome. Human Pathology 41(5): 758-762, 2010

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 117(10): 2935-2943, 2011

P-169 Presence of JAK2 V617F mutation in myeloproliferative and myelodysplastic syndrome patients. Leukemia Research 37: S99-S100, 2013

Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. Journal of Allergy and Clinical Immunology 126(1): 179-181, 2010

The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders. Haematologica 93(5): 787-788, 2008

Janus kinase (JAK2) V617F somatic mutation in patients with deep vein thrombosis. 2007